In summary, combining glycoengineering and DE point mutations greatly enhances antibody affinity for both FcγRIIIa polymorphic variants while retaining the Fab-mediated specific tumor antigen recognition, binding characteristics, and antiproliferative effects of the original clone. The gene discussed is FCGR3A; the disease is neoplasm.